

Christel Herold-Mende

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3312885/publications.pdf>

Version: 2024-02-01

150
papers

12,796
citations

66343

42
h-index

26613

107
g-index

154
all docs

154
docs citations

154
times ranked

16522
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
2	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. <i>Acta Neuropathologica</i> , 2009, 118, 469-474.	7.7	1,020
3	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
4	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405.	16.8	627
5	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 682-694.	10.7	586
6	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	10.7	582
7	Stem cell-associated heterogeneity in Glioblastoma results from intrinsic tumor plasticity shaped by the microenvironment. <i>Nature Communications</i> , 2019, 10, 1787.	12.8	379
8	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , 2018, 24, 1192-1203.	30.7	359
9	Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. <i>Journal of Clinical Investigation</i> , 2017, 127, 1425-1437.	8.2	334
10	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018, 136, 153-166.	7.7	298
11	Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF- β 2. <i>Clinical Cancer Research</i> , 2011, 17, 4296-4308.	7.0	290
12	TERT Promoter Mutations and Risk of Recurrence in Meningioma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv377.	6.3	283
13	Differentiation Therapy Exerts Antitumor Effects on Stem-like Glioma Cells. <i>Clinical Cancer Research</i> , 2010, 16, 2715-2728.	7.0	279
14	Long Noncoding RNA TARID Directs Demethylation and Activation of the Tumor Suppressor TCF21 via GADD45A. <i>Molecular Cell</i> , 2014, 55, 604-614.	9.7	242
15	Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. <i>Radiology</i> , 2016, 281, 907-918.	7.3	236
16	When Immune Cells Turn Bad—Tumor-Associated Microglia/Macrophages in Glioma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 436.	4.1	231
17	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , 2016, 131, 903-910.	7.7	203
18	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. <i>Acta Neuropathologica</i> , 2018, 136, 793-803.	7.7	195

#	ARTICLE	IF	CITATIONS
19	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	1.2	184
20	Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. <i>Cancer Cell</i> , 2019, 35, 692-704.e12.	16.8	172
21	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. <i>Acta Neuropathologica</i> , 2017, 133, 629-644.	7.7	146
22	Different angiogenic phenotypes in primary and secondary glioblastomas. <i>International Journal of Cancer</i> , 2006, 118, 2182-2189.	5.1	126
23	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413.	7.7	116
24	Acyl-CoA-Binding Protein Drives Glioblastoma Tumorigenesis by Sustaining Fatty Acid Oxidation. <i>Cell Metabolism</i> , 2019, 30, 274-289.e5.	16.2	115
25	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. <i>Acta Neuropathologica</i> , 2018, 135, 955-963.	7.7	109
26	MYCN amplification drives an aggressive form of spinal ependymoma. <i>Acta Neuropathologica</i> , 2019, 138, 1075-1089.	7.7	104
27	Advances in multidisciplinary therapy for meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i18-i31.	1.2	102
28	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 95-105.	1.2	100
29	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852.	1.6	93
30	EXPRESSION OF CD44 SPLICE VARIANTS IN SQUAMOUS EPITHELIA AND SQUAMOUS CELL CARCINOMAS OF THE HEAD AND NECK. , 1996, 179, 66-73.		79
31	Mechanistic Studies on a Novel, Highly Potent Gold-Phosphole Inhibitor of Human Glutathione Reductase. <i>Journal of Biological Chemistry</i> , 2005, 280, 20628-20637.	3.4	78
32	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. <i>Acta Neuropathologica</i> , 2015, 130, 419-434.	7.7	74
33	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. <i>Acta Neuropathologica</i> , 2019, 138, 295-308.	7.7	74
34	Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. <i>International Journal of Cancer</i> , 1999, 80, 194-198.	5.1	70
35	Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. <i>Oncotarget</i> , 2016, 7, 31955-31971.	1.8	69
36	Carbon irradiation overcomes glioma radioresistance by eradicating stem cells and forming an antiangiogenic and immunopermissive niche. <i>JCI Insight</i> , 2019, 4, .	5.0	63

#	ARTICLE	IF	CITATIONS
37	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2016, 118, 350-358.	0.6	62
38	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. <i>Acta Neuropathologica</i> , 2019, 138, 497-504.	7.7	57
39	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. <i>Acta Neuropathologica</i> , 2018, 136, 293-302.	7.7	56
40	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. <i>Clinical Cancer Research</i> , 2019, 25, 1851-1866.	7.0	55
41	Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma. <i>Journal of Pathology</i> , 2014, 234, 23-33.	4.5	53
42	The genomic and transcriptional landscape of primary central nervous system lymphoma. <i>Nature Communications</i> , 2022, 13, 2558.	12.8	52
43	Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. <i>BMC Cancer</i> , 2016, 16, 81.	2.6	51
44	Association of Stem Cell-Related Markers and Survival in Astrocytic Gliomas. <i>Biomarkers</i> , 2011, 16, 136-143.	1.9	46
45	Radiosensitivity of Patient-Derived Glioma Stem Cell 3-Dimensional Cultures to Photon, Proton, and Carbon Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 112-119.	0.8	46
46	YAP1-fusions in pediatric NF2-wildtype meningioma. <i>Acta Neuropathologica</i> , 2020, 139, 215-218.	7.7	45
47	IDH1 mutations induce organelle defects via dysregulated phospholipids. <i>Nature Communications</i> , 2021, 12, 614.	12.8	44
48	Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event. <i>PLoS ONE</i> , 2012, 7, e41298.	2.5	43
49	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. <i>Acta Neuropathologica</i> , 2019, 138, 827-835.	7.7	42
50	MetaboDiff: an R package for differential metabolomic analysis. <i>Bioinformatics</i> , 2018, 34, 3417-3418.	4.1	41
51	Expression and regulation of AC133 and CD133 in glioblastoma. <i>Glia</i> , 2011, 59, 1974-1986.	4.9	40
52	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. <i>Neuro-Oncology</i> , 2017, 19, 1607-1617.	1.2	39
53	Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. <i>Cancer Science</i> , 2011, 102, 387-392.	3.9	38
54	Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients. <i>International Journal of Cancer</i> , 2014, 135, 2727-2734.	5.1	38

#	ARTICLE	IF	CITATIONS
55	Comparison of the RGD Motifâ€“Containing Î±_vÎ²₆ Integrinâ€“Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1679-1685.	5.0	38
56	Antiglioma activity of 2,2â€²:6â€²,2â€²-terpyridineplatinum(II) complexes in a rat modelâ€“Effects on cellular redox metabolism. <i>Free Radical Biology and Medicine</i> , 2006, 40, 763-778.	2.9	37
57	Identification of a Novel ITCÎ±vÎ²6-Binding Peptide Using Protein Separation and Phage Display. <i>Clinical Cancer Research</i> , 2017, 23, 4170-4180.	7.0	37
58	Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. <i>Oncotarget</i> , 2016, 7, 14551-14568.	1.8	36
59	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylationâ€“the NCT Neuro Master Match (N2M2) pilot study. <i>Neuro-Oncology</i> , 2018, 20, 826-837.	1.2	32
60	Identification of KIF11 As a Novel Target in Meningioma. <i>Cancers</i> , 2019, 11, 545.	3.7	31
61	Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 480-492.	1.2	31
62	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. <i>Acta Neuropathologica</i> , 2021, 141, 281-290.	7.7	31
63	Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2903.	4.1	30
64	Expansive growth of two glioblastoma stem-like cell lines is mediated by bFGF and not by EGF. <i>Radiology and Oncology</i> , 2013, 47, 330-337.	1.7	29
65	Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck. <i>Oral Oncology</i> , 2004, 40, 28-35.	1.5	28
66	Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. <i>Acta Neuropathologica Communications</i> , 2018, 6, 21.	5.2	28
67	Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer. <i>Clinical Neurology and Neurosurgery</i> , 2016, 142, 72-80.	1.4	26
68	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. <i>Acta Neuropathologica</i> , 2017, 134, 155-158.	7.7	26
69	Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis. <i>Journal of Neuro-Oncology</i> , 2016, 129, 319-328.	2.9	25
70	Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 2951-2962.	7.0	25
71	Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma. <i>Cancers</i> , 2019, 11, 122.	3.7	25
72	Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 2005-2014.	4.2	24

#	ARTICLE	IF	CITATIONS
73	AN1-type zinc finger protein 3 (ZFAND3) is a transcriptional regulator that drives Glioblastoma invasion. <i>Nature Communications</i> , 2020, 11, 6366.	12.8	24
74	Cannabidiol converts NF- κ B into a tumor suppressor in glioblastoma with defined antioxidative properties. <i>Neuro-Oncology</i> , 2021, 23, 1898-1910.	1.2	24
75	Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. <i>Acta Neuropathologica</i> , 2017, 134, 297-316.	7.7	23
76	Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin. <i>Cancers</i> , 2019, 11, 2028.	3.7	23
77	Association of Drug Transporter Expression with Mortality and Progression-Free Survival in Stage IV Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e108908.	2.5	22
78	Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. <i>Neuro-Oncology</i> , 2021, 23, 226-239.	1.2	22
79	A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma. <i>Neuro-Oncology</i> , 2022, 24, 39-51.	1.2	22
80	PET/CT Imaging of NSCLC with a α 6 Integrin-Targeting Peptide. <i>Molecular Imaging and Biology</i> , 2019, 21, 973-983.	2.6	21
81	FASN Is a Biomarker Enriched in Malignant Glioma-Derived Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1931.	4.1	20
82	Pediatric and Adult High-Grade Glioma Stem Cell Culture Models Are Permissive to Lytic Infection with Parvovirus H-1. <i>Viruses</i> , 2016, 8, 138.	3.3	19
83	Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 593-603.	4.2	19
84	DNA methylation at an enhancer of the three prime repair exonuclease 2 gene (TREX2) is linked to gene expression and survival in laryngeal cancer. <i>Clinical Epigenetics</i> , 2019, 11, 67.	4.1	19
85	Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study. <i>Acta Neuropathologica</i> , 2022, 143, 609-612.	7.7	19
86	Antitumor Immunization of Head and Neck Squamous Cell Carcinoma Patients with a Virus-Modified Autologous Tumor Cell Vaccine. , 2004, 62, 173-183.		18
87	Epigenetically mediated downregulation of the differentiation-promoting chaperon protein CRABP2 in astrocytic gliomas. <i>International Journal of Cancer</i> , 2012, 131, 1963-1968.	5.1	18
88	<i>LOC283731</i> promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. <i>International Journal of Cancer</i> , 2016, 139, 424-432.	5.1	18
89	Volumetric assessment of glioblastoma and its predictive value for survival. <i>Acta Neurochirurgica</i> , 2019, 161, 1723-1732.	1.7	18
90	Gliosarcoma Is Driven by Alterations in PI3K/Akt, RAS/MAPK Pathways and Characterized by Collagen Gene Expression Signature. <i>Cancers</i> , 2019, 11, 284.	3.7	18

#	ARTICLE	IF	CITATIONS
91	Oligosarcomas, IDH-mutant are distinct and aggressive. <i>Acta Neuropathologica</i> , 2022, 143, 263-281.	7.7	18
92	Association Between Tumor Compartment Volumes, the Incidence of Pretreatment Seizures, and Statin-Mediated Protective Effects in Glioblastoma. <i>Neurosurgery</i> , 2019, 85, E722-E729.	1.1	17
93	Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents. <i>Cells</i> , 2020, 9, 1389.	4.1	17
94	KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. <i>Cancer Letters</i> , 2021, 506, 1-10.	7.2	17
95	Identification of Ligands and Translation to Clinical Applications. <i>Journal of Nuclear Medicine</i> , 2017, 58, 27S-33S.	5.0	16
96	Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. <i>Cancers</i> , 2019, 11, 1072.	3.7	16
97	Clinical and immunological correlates of long term survival in glioblastoma. <i>Wspolczesna Onkologia</i> , 2018, 2018, 81-85.	1.4	15
98	A PRDX1â€³38â€± heterodimer amplifies METâ€³driven invasion of <i>IDH</i>â€³wildtype and <i>IDH</i>â€³mutant gliomas. <i>International Journal of Cancer</i> , 2018, 143, 1176-1187.	5.1	14
99	Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition. <i>Cancer & Metabolism</i> , 2020, 8, 23.	5.0	14
100	Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. <i>Glia</i> , 2015, 63, 1850-1859.	4.9	13
101	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. <i>Acta Neuropathologica</i> , 2017, 133, 325-327.	7.7	12
102	Human papilloma virus (HPV) 18 proteins E6 and E7 up-regulate ABC transporters in oropharyngeal carcinoma. Involvement of the nonsense-mediated decay (NMD) pathway. <i>Cancer Letters</i> , 2018, 428, 69-76.	7.2	12
103	Calcitriol Promotes Differentiation of Glioma Stem-Like Cells and Increases Their Susceptibility to Temozolomide. <i>Cancers</i> , 2021, 13, 3577.	3.7	12
104	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. <i>Acta Neuropathologica Communications</i> , 2022, 10, 5.	5.2	12
105	Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC. <i>Cancers</i> , 2018, 10, 486.	3.7	11
106	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018, 136, 975-978.	7.7	11
107	Radioresistance and Transcriptional Reprograming of Invasive Glioblastoma Cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 499-513.	0.8	10
108	Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 1065-1074.	1.7	10

#	ARTICLE	IF	CITATIONS
109	Helping EGFR inhibition to block cancer. <i>Nature Neuroscience</i> , 2017, 20, 1035-1037.	14.8	9
110	Impact of post-surgical freezing delay on brain tumor metabolomics. <i>Metabolomics</i> , 2019, 15, 78.	3.0	9
111	The anesthetist's choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients. <i>Neurosurgical Review</i> , 2021, 44, 2707-2715.	2.4	9
112	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making – A Selected Case Series. <i>Klinische Padiatrie</i> , 2018, 230, 305-313.	0.6	8
113	Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. <i>International Journal of Cancer</i> , 2019, 145, 3436-3444.	5.1	8
114	Preclinical evaluation of peptide-based radiotracers for integrin $\alpha_6\beta_1$ -positive pancreatic carcinoma. <i>Nuklearmedizin - Nuclear Medicine</i> , 2019, 58, 309-318.	0.7	8
115	Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7801.	4.1	8
116	Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma. <i>Cancers</i> , 2020, 12, 3270.	3.7	8
117	Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz060.	0.7	8
118	The pregnane X receptor (PXR) and the nuclear receptor corepressor 2 (NCoR2) modulate cell growth in head and neck squamous cell carcinoma. <i>PLoS ONE</i> , 2018, 13, e0193242.	2.5	8
119	Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , 2014, 15, 436-442.	3.4	7
120	Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo. <i>Cancers</i> , 2021, 13, 5898.	3.7	7
121	Cortactin expression: Association with disease progression and survival in oral squamous cell carcinoma. <i>Head and Neck</i> , 2018, 40, 2685-2694.	2.0	6
122	RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas. <i>Acta Neuropathologica</i> , 2019, 138, 275-293.	7.7	6
123	Gold(III) complexes based on six-membered phosphorus heterocycles as bio-active molecules against brain cancer. <i>Chemical Communications</i> , 2020, 56, 14593-14596.	4.1	6
124	Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma. <i>Cancers</i> , 2020, 12, 2583.	3.7	6
125	A New Pentafluorothio-Substituted Curcuminoid with Superior Antitumor Activity. <i>Biomolecules</i> , 2021, 11, 947.	4.0	6
126	STAT3 Enhances Sensitivity of Glioblastoma to Drug-Induced Autophagy-Dependent Cell Death. <i>Cancers</i> , 2022, 14, 339.	3.7	6

#	ARTICLE	IF	CITATIONS
127	Combined Treatment of ATRA with Epigenetic Drugs Increases Aggressiveness of Glioma Xenografts. <i>Anticancer Research</i> , 2016, 36, 1489-96.	1.1	6
128	Diagnostic potential of extracellular vesicles in meningioma patients. <i>Neuro-Oncology</i> , 2022, 24, 2078-2090.	1.2	6
129	Integrated Metabolomics and Transcriptomics Analysis of Monolayer and Neurospheres from Established Glioblastoma Cell Lines. <i>Cancers</i> , 2021, 13, 1327.	3.7	5
130	Luminescent Pyrrole-Based Phosphaphenylene Gold Complexes: A Versatile Anticancer Tool with a Wide Applicability. <i>Chemistry - A European Journal</i> , 2022, , .	3.3	5
131	Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2960.	4.1	4
132	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N ² M ²).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2084-TPS2084.	1.6	4
133	VXM01 phase I study in patients with resectable progression of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2061-2061.	1.6	4
134	Lessons we Learned from High-Throughput and Top-Down Systems Biology Analyses about Glioma Stem Cells. <i>Current Pharmaceutical Design</i> , 2014, 20, 66-72.	1.9	4
135	HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. <i>Neuro-Oncology</i> , 2022, , .	1.2	4
136	Luminescent Pyrrole-Based Phosphaphenylene Gold Complexes: Versatile Anticancer Tools with Wide Applicability. <i>Chemistry - A European Journal</i> , 2022, 28, .	3.3	4
137	Non-invasive glioblastoma immunoprofiling by printed peptide arrays. <i>Oncolmmunology</i> , 2016, 5, e1069941.	4.6	3
138	An Observational Cohort Study on 194 Supraglottic Cancer Patients: Implications for Laser Surgery and Adjuvant Treatment. <i>Cancers</i> , 2021, 13, 568.	3.7	3
139	Glioblastoma evolution pattern under surgery and radio(chemo)therapy (RCHT) to identify novel methylome based glioma subtypes.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2012-2012.	1.6	3
140	Could Primary Chemoradiotherapy in T2 Glottic Cancers Yield Results Comparable to Primary Radiotherapy in T1? Considerations from 531 German Early Stage Patients. <i>Cancers</i> , 2021, 13, 1601.	3.7	2
141	Chemoradiotherapy but Not Radiotherapy Alone for Larynx Preservation in T3. Considerations from a German Observational Cohort Study. <i>Cancers</i> , 2021, 13, 3435.	3.7	2
142	Whole Blood Transcriptional Fingerprints of High-Grade Glioma and Longitudinal Tumor Evolution under Carbon Ion Radiotherapy. <i>Cancers</i> , 2022, 14, 684.	3.7	2
143	PD-L1-R: A MR based surrogate for PD-L1 expression in Glioblastoma multiforme.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2041-2041.	1.6	1
144	DDIS-21. KIF11 INHIBITORS FILANESIB AND ISPINESIB AS NOVEL AGENTS FOR MENINGIOMA THERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi73-vi73.	1.2	0

#	ARTICLE	IF	CITATIONS
145	MBRS-12. INTERFERENCE WITH THE FUNCTION OF MYC IN GROUP 3 MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i130-i130.	1.2	0
146	SURG-19. IMPACT OF INTRAOPERATIVE MAGNETIC RESONANCE IMAGING ON THE EXTENT OF RESECTION AND FUNCTIONAL OUTCOME IN AWAKE SURGERY FOR ELOQUENT GLIOMAS – A SINGLE CENTER RETROSPECTIVE STUDY. <i>Neuro-Oncology</i> , 2018, 20, vi254-vi254.	1.2	0
147	Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study. , 2019, 80, .		0
148	Endothelial Cells Derived from Non-malignant Tissues Are of Limited Value as Models for Brain Tumor Vasculature. <i>Anticancer Research</i> , 2015, 35, 2681-90.	1.1	0
149	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) and <i>in vivo</i> validation. <i>Neuro-Oncology</i> , 2022, 24, i168-i169.	1.2	0
150	LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. <i>Neuro-Oncology</i> , 2022, 24, i91-i92.	1.2	0